Clinical Trial

Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-31.
Trial Details
NCT Number NCT06762470
Lead Sponsor Jiangxi Provincial Cancer Hospital
Conditions Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Enrollment 325 participants
Start Date 2025-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-09